A Case Report of a Well-Differentiated Neuroendocrine Tumor in which Sunitinib Treatment Resulted an Effective Response of Disease Abstract #2157

Introduction: A case report of no pancreatic well-differentiated neuroendocrine tumor in which sunitinib treatment resulted an effective response of disease
Aim(s): A 24 year old man had a primary carcinoid tumor (NET 2) with multiple liver metastasis and ileal tumor, Since no drug were approved for NETS at that time in Algeria,
Materials and methods: We treated him after surgery of the primary and sandostatine LAR with sunitinib after approval by my head of my department of oncology and informed consent of the patient , Sunitinib was administered at daily dose of 37,5 mg/day with good tolerability since 2010 ,The non-hematological toxicity was hand and foot syndrome (G2) and controlled with topics and fatigue (G2 ) , CT revealed stable disease after 3 months of treatment for 36 months with safety profile than PR of liver metastasis with therapeutic windows sometimes . we preconize surgery in 6 of June 2014 and we obtain very good response and no liver lesion in the CT of April 2015 than we decided to maintain the patient under 25 mg of sunitinib because he had asthenia (G2 and sometimes G3)
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: PH Radia Sai
Authors: SAI R

To read results and conclusion, please login ...

Further abstracts you may be interested in

#127 Sunitinib for the treatment of advanced, progressive pancreatic neuroendocrine tumors
Introduction: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor approved for use in advanced renal cell carcinoma and imatinib-resistant/intolerant gastrointestinal stromal tumors. Investigations of sunitinib in the RIP1-Tag2 mouse model and in phase I/II clinical trials provide evidence of antitumor activity against pancreatic neuroendocrine tumors (NET).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Eric Raymond
#514 Cost-Effectiveness of Sunitinib in Patients (Pts) with Advanced or Metastatic Pancreatic Neuroendocrine Tumors (pNET) in the Netherlands
Introduction: Sunitinib (SU) is an oral multitargeted tyrosine kinase inhibitor approved and reimbursed in the Netherlands for use in advanced/metastatic well-differentiated pNET.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Huib Scheijbeler
#708 Sunitinib in Pancreatic Neuroendocrine Tumors
Introduction: Sunitinib has shown significant improvement of progression-free survival in patients with advanced pancreatic neuroendocrine tumors (pNET).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Harald Lahner
Keywords: sunitinib, pNET
#712 A Retrospective Analysis of Safety and Efficacy of Everolimus in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients That Showed Progression after PRRT
Introduction: GEP-NET patients have been treated successfully with SSAs. Upon progression, peptide receptor radiotherapy (PRRT) with 177Lu-octreotate is successful. PRRT is not unlimited. Some patients became refractory after therapy. There is a high medical need. Everolimus (mTOR inhibitor) is a promising therapy for progressive G1/G2 GEP-NETs, with well-established safety. Everolimus has shown efficacy in patients with (non-)PNET (RADIANT-2/-3). However, toxicity data of Everolimus after PRRT is lacking.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: drs. Kimberly Kamp
Authors: Kamp K, Feelders R, De Herder W, ...
#846 Effects of Sunitinib in Combination with Octreotide LAR for Patients with Advanced Pancreatic Neuroendocrine Tumor which Failed Sunitinib or Octreotide LAR Alone
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Others
Presenting Author: Chunmei Bai
Authors: Ying H, Cheng Y, Sun Z, Xue H, ...